Real-world baseline characteristics and diagnostic path of Polish patients with ALK-positive NSCLC eligible for brigatinib treatment: Interim results from the ENTIRETY study. This is an ASCO Meeting ...
HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...
Afatinib almost doubled progression-free survival versus chemotherapy in advanced lung cancer with uncommon EGFR mutations. The treatment effect was consistent across major uncommon mutations, ...
Patients with EGFR pathway and Fusion Positive mutations had higher Healthy Eating Index-2020 scores than U.S. reference.
The US Food and Drug Administration (FDA) today approved the first blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer ...
An early clinical trial found that setidegrasib, a therapy designed to eliminate KRAS G12D proteins, shrank tumors and ...
A new research paper was published in Volume 16 of Oncotarget on June 17, 2025, titled "Molecular landscape of HER2-mutated non-small cell lung cancer in Northeastern Brazil: Clinical, ...
Researchers uncover how mutant lung cells reshape surrounding tissue through signaling loops with fibroblasts and immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results